Skip to main content
Elsevier Sponsored Documents logoLink to Elsevier Sponsored Documents
. 2025 Feb 5;84(2):373. doi: 10.1136/ard-2023-225473corr1

Correction: Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment

PMCID: PMC12677154  PMID: 39919910

Feist E, Fleischmann RM, Fatenejad S, et al. Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment. Annals of the Rheumatic Diseases 2024;83:1454-1464.

The correct Figure 2, Figure 3 including descriptions provided on y-axis are below:

Figure 2.

Figure 2

Figure 3.

Figure 3

RESOURCES